Peramivir sales in Japan

Shionogi announced Peramivir sales targets for their fiscal year ending March 31, 2010.

http://www.shionogi.co.jp/ir_en/news/detail/e_100126.pdf

Based on conservative estimates of 700,000 doses at $34 per dose to $64 per dose, Shionogi expects revenue of between $23.8 million and $44.i million. With an assumed 20% royalty split, BioCryst Pharmaceuticals (BCRX) revenue from Shionogi sales in Japan over the next two months is between $4.76 million to $8.82 million. These revenue figures flow straight to the bottom line, and with 38.2 million outstanding shares, the earnings per share from Japanese revenue over the next two months is significant.

Sales figures do not take into account milestone payments due BCRX, and do not include the manufacturing mark-up from sales of Peramivir Active Pharmaceutical Ingredient (API) to Shionogi.

As noted, Peramivir is gaining traction worldwide, as regulatory approvals and emergency use authorization (EUA) have been secured in North America, Asia, Europe, the Middle East, and Latin America.

See sidebar for disclaimers.

Disclosure: long BCRX shares.